Vyome secures exclusive license from Impetis for selective JAK inhibitor programs
The global JAK inhibitors market is projected to REACH $56.78 billion by 2030, reflecting strong demand for targeted immunology treatments
The global JAK inhibitors market is projected to REACH $56.78 billion by 2030, reflecting strong demand for targeted immunology treatments
Indomo’s ClearPen system combines a proprietary self-injection device and microneedle with a modernized triamcinolone acetonide formulation
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
Subscribe To Our Newsletter & Stay Updated